Company Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2010 |
| IPO Date | Dec 7, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5,600 |
| CEO | Stephane Bancel |
Contact Details
Address: 325 Binney Street Cambridge, Massachusetts 02142 United States | |
| Phone | (617) 714-6500 |
| Website | modernatx.com |
Stock Details
| Ticker Symbol | MRNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001682852 |
| CUSIP Number | 60770K107 |
| ISIN Number | US60770K1079 |
| Employer ID | 81-3467528 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Stephane Bancel | Chief Executive Officer and Director |
| Dr. Stephen Hoge M.D. | President |
| James M. Mock | Chief Financial Officer |
| Shannon Thyme Klinger | Chief Legal Officer and Corporate Secretary |
| Dr. Jerh Collins Ph.D. | Chief Technical Operations and Quality Officer |
| Brad Miller | Chief Information Officer |
| Lavina Talukdar CFA | Senior Vice President and Head of Investor Relations |
| Colleen Hussey | Senior Director of Corporate Communications |
| Tracey Franklin | Chief Human Resources Officer |
| Dr. Melanie Ivarsson M.B.A., Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 144 | Filing |
| Apr 15, 2024 | 144 | Filing |
| Apr 10, 2024 | 144 | Filing |
| Apr 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 8, 2024 | 144 | Filing |
| Apr 3, 2024 | 144 | Filing |
| Mar 27, 2024 | 144 | Filing |
| Mar 21, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 21, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2024 | 144 | Filing |